Nexara Health — Health Canada Drug Establishment Licence #3-002896

Trial comparator supply from Canada

Every trial below uses at least one comparator that is marketed in Canada, which means the comparator can be supplied with the Canadian label, Certificate of Analysis, batch number and expiry documentation, without a Special Access request. Nexara Health supplies comparator, rescue and ancillary medication to sponsors and CROs under Health Canada Drug Establishment Licence #3-002896 from Winnipeg, Manitoba.

Comparator supply fails for predictable reasons: the presentation available locally does not match the protocol, the shortage hits mid-study, or the source market cannot document the chain of custody an auditor expects. Sourcing the comparator from Canada solves the first two and documents the third. The list below is refreshed from the public trial registry; each page shows the marketed Canadian products, the manufacturers behind them, and the strengths that can be supplied.

NCTTrialComparatorSponsorStatusUpdated
NCT03914612Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplcarboplatin hexalNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT05915104Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitisbudesonide controlled ileal release (cr) capsulesUniversity of CalgaryActive Not Recruiting2026-10-21
NCT07524530Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancersmycophenolate mofetilNational Cancer Institute (NCI)Not Yet Recruiting2026-10-21
NCT03907475Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trialpaclitaxel nanoparticle albumin-boundNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05502341Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With alenacapavirGilead SciencesActive Not Recruiting2026-10-21
NCT05914116A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsitraconazoleDualityBio Inc.Recruiting2026-10-21
NCT07286214Sarilumab Efficacy and Safety in Adults With Early Polymyalgia RheumaticasarilumabSanofiRecruiting2026-10-21
NCT07524530Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersfludarabineNational Cancer Institute (NCI)Not Yet Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute LymphmercaptopurineNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT03907475Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trialpaclitaxel albumin-stabilized nanoparticle formulationNational Cancer Institute (NCI)Recruiting2026-10-21
NCT04924075Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor belzutifanMerck Sharp & Dohme LLCRecruiting2026-10-21
NCT05476939Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0everolimusGustave Roussy, Cancer Campus, Grand ParisRecruiting2026-10-21
NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment WivenetoclaxNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05914116A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsenzalutamideDualityBio Inc.Recruiting2026-10-21
NCT07198074Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With carboplatin hexalNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07267338Pembrolizumab + MRGOO3 as Neoadjuvant in NPCpembrolizumab & mrg003Union Hospital, Tongji Medical College, Huazhong University Active Not Recruiting2026-10-21
NCT07437950Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myeldecitabine and cedazuridineNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07524530Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancerscyclophosphamideNational Cancer Institute (NCI)Not Yet Recruiting2026-10-21
NCT07775313Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMplerixaforNational Institute of Allergy and Infectious Diseases (NIAIDEnrolling By Invitation2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute LymphleucovorinNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT03713879Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP PancreatitisindomethacinChinese University of Hong KongRecruiting2026-10-21
NCT03907475Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trialpaclitaxel albuminNational Cancer Institute (NCI)Recruiting2026-10-21
NCT04526665Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)elafibranor 80mgIpsenActive Not Recruiting2026-10-21
NCT04781088Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, orpaclitaxelFloor Backes, MDActive Not Recruiting2026-10-21
NCT05048797A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable,cisplatinAstraZenecaActive Not Recruiting2026-10-21
NCT05468554Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid CancermetforminMedical University of BialystokRecruiting2026-10-21
NCT05554406Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatmencytarabine and daunorubicin liposomalNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment WiquizartinibNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabdacarbazine - dticNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05914116A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsabirateroneDualityBio Inc.Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute LymphpegaspargaseNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT03907475Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trialpaclitaxel protein-boundNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07596784Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)ravulizumabAlexion Pharmaceuticals, Inc.Recruiting2026-10-21
NCT07262983Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or AtopibaricitinibNational Institute of Allergy and Infectious Diseases (NIAIDRecruiting2026-10-21
NCT07405164Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)cabozantinibMerck Sharp & Dohme LLCRecruiting2026-10-21
NCT07405671Flecainide Safety in Patients With Coronary Artery Disease and Atrial FibrillationflecainideUniversitaire Ziekenhuizen KU LeuvenRecruiting2026-10-21
NCT07437950Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyelvenetoclaxNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07524530Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersbusulfanNational Cancer Institute (NCI)Not Yet Recruiting2026-10-21
NCT01220583Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That cisplatinRadiation Therapy Oncology GroupActive Not Recruiting2026-10-21
NCT07775313Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMfilgrastimNational Institute of Allergy and Infectious Diseases (NIAIDEnrolling By Invitation2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute LymphdoxorubicinNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute LymphifosfamideNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT03299049Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Hucabotegravir tabletsViiV HealthcareActive Not Recruiting2026-10-21
NCT03703271Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neopmethotrexate chemotherapyWomen's Hospital School Of Medicine Zhejiang UniversityRecruiting2026-10-21
NCT06043674Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transforpolatuzumab vedotinChristine RyanRecruiting2026-10-21
NCT03907475Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialpaclitaxelNational Cancer Institute (NCI)Recruiting2026-10-21
NCT04194944A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell LungcisplatinEli Lilly and CompanyActive Not Recruiting2026-10-21
NCT04412629Cabozantinib in High Grade Neuroendocrine NeoplasmscabozantinibWashington University School of MedicineActive Not Recruiting2026-10-21
NCT04671667Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of ChcarboplatinNational Cancer Institute (NCI)Recruiting2026-10-21
NCT04781088Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, orlenvatinibFloor Backes, MDActive Not Recruiting2026-10-21
NCT05043090Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally AdvancedsunitinibAstraZenecaActive Not Recruiting2026-10-21
NCT05048797A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable,carboplatinAstraZenecaActive Not Recruiting2026-10-21
NCT05048797A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable,trastuzumab deruxtecanAstraZenecaActive Not Recruiting2026-10-21
NCT05139017A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or RefractooxaliplatinMerck Sharp & Dohme LLCRecruiting2026-10-21
NCT06279364A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic TriplepaclitaxelSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Active Not Recruiting2026-10-21
NCT05554406Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started TreatmencytarabineNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment WibusulfanNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wimelphalan for injection-hepatic delivery systemNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06834282CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)fludarabineCERo Therapeutics Holdings, Inc.Recruiting2026-10-21
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabcyclophosphamide monohydrateNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05838768Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite InstabiliirinotecanNovartis PharmaceuticalsActive Not Recruiting2026-10-21
NCT06810544Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossabemaciclibTango Therapeutics, Inc.Recruiting2026-10-21
NCT07887399New Treatment in Melasmatranexamic acid - topicalSohag UniversityNot Yet Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphmethotrexate methylaminopterinNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphvincristine sulfateNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT03279692Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade MeningiomapembrolizumabMassachusetts General HospitalActive Not Recruiting2026-10-21
NCT07572136Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TfludarabineNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07588945daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCTruxolitinibInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet Recruiting2026-10-21
NCT07222761A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care CdaratumumabRegeneron PharmaceuticalsRecruiting2026-10-21
NCT07222761A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care CpomalidomideRegeneron PharmaceuticalsRecruiting2026-10-21
NCT07345325Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditirifampin containing regimenNantes University HospitalRecruiting2026-10-21
NCT07405164Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)belzutifanMerck Sharp & Dohme LLCRecruiting2026-10-21
NCT07405164Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)lenvatinibMerck Sharp & Dohme LLCRecruiting2026-10-21
NCT07405164Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)nivolumabMerck Sharp & Dohme LLCRecruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute LymphbortezomibNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute LymphcyclophosphamideNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT07489495A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-0belzutifanMerck Sharp & Dohme LLCRecruiting2026-10-21
NCT07509034Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With RecfludarabineNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07524530Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancerstacrolimusNational Cancer Institute (NCI)Not Yet Recruiting2026-10-21
NCT07735637A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants WithfludarabineAstraZenecaRecruiting2026-10-21
NCT07756840Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)bevacizumabNational Cancer Institute (NCI)Not Yet Recruiting2026-10-21
NCT07775313Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMbusulfanNational Institute of Allergy and Infectious Diseases (NIAIDEnrolling By Invitation2026-10-21
NCT07811193A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in PapembrolizumabVividion Therapeutics, Inc.Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphdexamethasone intensolNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphhydrocortisone 21-sodium succinateNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphhydrocortisone sodium succinateNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT05761756Oxygen Toxicity: Mechanisms in HumansmethylphenidateDuke UniversityRecruiting2026-10-21
NCT03299049Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Hucabotegravir injectable suspensionViiV HealthcareActive Not Recruiting2026-10-21
NCT05761756Oxygen Toxicity: Mechanisms in HumanscaffeineDuke UniversityRecruiting2026-10-21
NCT03703271Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic NeopmethotrexateWomen's Hospital School Of Medicine Zhejiang UniversityRecruiting2026-10-21
NCT06043674Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransforatezolizumabChristine RyanRecruiting2026-10-21
NCT06043674Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransforpirtobrutinibChristine RyanRecruiting2026-10-21
NCT03907475Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialcapecitabineNational Cancer Institute (NCI)Recruiting2026-10-21
NCT03907475Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trialdoxorubicin hydrochloride liposomeNational Cancer Institute (NCI)Recruiting2026-10-21
NCT03914612Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and CarboplpaclitaxelNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT04194944A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell LungcarboplatinEli Lilly and CompanyActive Not Recruiting2026-10-21
NCT04194944A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell LungselpercatinibEli Lilly and CompanyActive Not Recruiting2026-10-21
NCT04404283Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCLrituximabSeagen, a wholly owned subsidiary of PfizerActive Not Recruiting2026-10-21
NCT04606446Study of PF-07248144 in Advanced or Metastatic Solid TumorsfulvestrantPfizerRecruiting2026-10-21
NCT04661007To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants WtafasitamabIncyte Biosciences Japan GKActive Not Recruiting2026-10-21
NCT04776525Sequential Neoadjuvant Chemotherapy in Soft Tissue SarcomadoxorubicinOslo University HospitalRecruiting2026-10-21
NCT04776525Sequential Neoadjuvant Chemotherapy in Soft Tissue SarcomaifosfamideOslo University HospitalRecruiting2026-10-21
NCT05043090Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally AdvanceddurvalumabAstraZenecaActive Not Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute LymphdexamethasoneNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT04421560Pembrolizumab, Ibrutinib and Rituximab in PCNSLrituximabDana-Farber Cancer InstituteRecruiting2026-10-21
NCT04472949Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in ExtensivetoposideSwiss Cancer InstituteActive Not Recruiting2026-10-21
NCT05048797A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable,pemetrexedAstraZenecaActive Not Recruiting2026-10-21
NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Widecitabine and cedazuridineNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05061550Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerdurvalumabAstraZenecaRecruiting2026-10-21
NCT05139017A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or RefractogemcitabineMerck Sharp & Dohme LLCRecruiting2026-10-21
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed vincristineNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07887672A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed MultiplelenalidomideKite, A Gilead CompanyNot Yet Recruiting2026-10-21
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed topotecanNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05554406Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started TreatmenazacitidineNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06279364A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic TripleeribulinSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Active Not Recruiting2026-10-21
NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment WiazacitidineNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment WigilteritinibNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment WimelphalanNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory AggressibrutinibNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06317662Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual CcrisantaspaseNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05578664Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancerpembrolizumab injection plus metastasis directed treatmentConsorzio OncotechActive Not Recruiting2026-10-21
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabcyclophosphamideNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabdoxorubicin hydrochlorideNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabprednisoloneNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06654882Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritistocilizumabDuke UniversityRecruiting2026-10-21
NCT06773026Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA sodium phenylbutyrateJerry Vockley, MD, PhDRecruiting2026-10-21
NCT07887022Randomized Interventional Clinical Trial on the Prevention of Atrial Fibrillation Using Colchicine, Amiodarone And a PosamiodaroneElsanNot Yet Recruiting2026-10-21
NCT07886905Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid CancertrametinibWashington University School of MedicineNot Yet Recruiting2026-10-21
NCT06995872Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/RefratemozolomideNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance CcisplatinNational Cancer Institute (NCI)Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphthioguanine hemihydrateNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute LymphvincristineNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT03122717Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerosimertinibDana-Farber Cancer InstituteActive Not Recruiting2026-10-21
NCT03179930Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory LymphomaspembrolizumabMemorial Sloan Kettering Cancer CenterActive Not Recruiting2026-10-21
NCT07198074Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With paclitaxelNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07572136Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TcyclophosphamideNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07885709MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCcarboplatinPeking University People's HospitalNot Yet Recruiting2026-10-21
NCT07572994Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndromelidocaine 2 %Cairo UniversityRecruiting2026-10-21
NCT07659795A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancercetuximab + mfolfox6Verastem, Inc.Recruiting2026-10-21
NCT07222761A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care CcarfilzomibRegeneron PharmaceuticalsRecruiting2026-10-21
NCT07222761A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care CdexamethasoneRegeneron PharmaceuticalsRecruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemiadexamethasone intensolNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT07886229Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung CatoripalimabSecond Xiangya Hospital of Central South UniversityRecruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiamethotrexateNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT07886229Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Capropranolol hydrochlorideSecond Xiangya Hospital of Central South UniversityRecruiting2026-10-21
NCT07393282A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)daratumumabRegeneron PharmaceuticalsRecruiting2026-10-21
NCT07886320Adapalene Gel for Acute Radiation-Induced Skin Injuryadapalene gel 0.1%Yunnan Cancer HospitalRecruiting2026-10-21
NCT07659795A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerpanitumumabVerastem, Inc.Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiavincristineNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemiamethotrexate lpfNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT07884734A Study to Evaluate the Effect of Carbamazepine or Itraconazole on Radiprodil in Healthy Adult ParticipantsitraconazoleGRIN Therapeutics, Inc.Active Not Recruiting2026-10-21
NCT07884773Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent β-ThalathalidomideKhyber Medical University PeshawarRecruiting2026-10-21
NCT07884773Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent β-ThalaprednisoloneKhyber Medical University PeshawarRecruiting2026-10-21
NCT07884773Combination Therapy With Danazol, Prednisolone, and Thalidomide for Thalidomide-Refractory Transfusion-Dependent β-ThaladanazolKhyber Medical University PeshawarRecruiting2026-10-21
NCT07572994Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndromelidocaine + sodium bicarbonateCairo UniversityRecruiting2026-10-21
NCT07884877PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Canceratezolizumab plus bevacizumabSamsung Medical CenterRecruiting2026-10-21
NCT07493304Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancapixabanRegeneron PharmaceuticalsRecruiting2026-10-21
NCT07509034Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With ReccyclophosphamideNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07884955Comparing Inclisiran Versus Statin for Primary AldosteronismspironolactoneThird Military Medical UniversityRecruiting2026-10-21
NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment WigemtuzumabNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07887022Randomized Interventional Clinical Trial on the Prevention of Atrial Fibrillation Using Colchicine, Amiodarone And a PoscolchicineElsanNot Yet Recruiting2026-10-21
NCT07884877PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver CancernivolumabSamsung Medical CenterRecruiting2026-10-21
NCT07884955Comparing Inclisiran Versus Statin for Primary AldosteronisminclisiranThird Military Medical UniversityRecruiting2026-10-21
NCT07735637A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants WithmelphalanAstraZenecaRecruiting2026-10-21
NCT07884955Comparing Inclisiran Versus Statin for Primary Aldosteronismamlodipine besylateThird Military Medical UniversityRecruiting2026-10-21
NCT07759336Personalized Analgesia Through Central Nervous System Engagement to Unlock PerformanceduloxetineBenedict AlterRecruiting2026-10-21
NCT07776691A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive AdbevacizumabMerck Sharp & Dohme LLCRecruiting2026-10-21
NCT07796360Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium ContrastgadobutrolNational Institute of Neurological Disorders and Stroke (NINNot Yet Recruiting2026-10-21
NCT07855250An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 InhibitiondigoxinSanofiActive Not Recruiting2026-10-21
NCT07855250An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 InhibitionrosuvastatinSanofiActive Not Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphdoxorubicin hydrochlorideNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute LymphetoposideNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphhydrocortisone na succinateNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT04606446Study of PF-07248144 in Advanced or Metastatic Solid TumorsletrozolePfizerRecruiting2026-10-21
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabprednisoneNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabprednisone intensolNational Cancer Institute (NCI)Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute LymphmethotrexateNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphmethotrexate lpfNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabvincristine sulfateNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabvinblastine sulfateNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05713799Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With ObesitymirabegronNational Institute of Diabetes and Digestive and Kidney DiseNot Yet Recruiting2026-10-21
NCT03586453Osimertinib In EGFR Mutant Lung CancerosimertinibDana-Farber Cancer InstituteActive Not Recruiting2026-10-21
NCT05761756Oxygen Toxicity: Mechanisms in Humanssodium bicarbonateDuke UniversityRecruiting2026-10-21
NCT05828069A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell HistioctovorafenibNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06043674Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransforglofitamabChristine RyanRecruiting2026-10-21
NCT06043674Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransforobinutuzumabChristine RyanRecruiting2026-10-21
NCT06043674Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransfortocilizumabChristine RyanRecruiting2026-10-21
NCT03728972Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal TypepembrolizumabMemorial Sloan Kettering Cancer CenterActive Not Recruiting2026-10-21
NCT03907475Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialcarboplatinNational Cancer Institute (NCI)Recruiting2026-10-21
NCT03907475Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trialcarboplatin hexalNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07887412Efficacy and Safety of Modafinil to Treat Fatigue in People With Mitochondrial Disease.modafinilKenneth Myers, MDNot Yet Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemiamethotrexate methylaminopterinNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT07887672A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed MultiplebortezomibKite, A Gilead CompanyNot Yet Recruiting2026-10-21
NCT07887672A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed MultiplecyclophosphamideKite, A Gilead CompanyNot Yet Recruiting2026-10-21
NCT04194944A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell LungpembrolizumabEli Lilly and CompanyActive Not Recruiting2026-10-21
NCT04194944A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell LungpemetrexedEli Lilly and CompanyActive Not Recruiting2026-10-21
NCT04404283Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCLbrentuximab vedotinSeagen, a wholly owned subsidiary of PfizerActive Not Recruiting2026-10-21
NCT04404283Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCLlenalidomideSeagen, a wholly owned subsidiary of PfizerActive Not Recruiting2026-10-21
NCT07679334Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast PhazacitidineRoswell Park Cancer InstituteNot Yet Recruiting2026-10-21
NCT04604067Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.acalabrutinibSwiss Cancer InstituteActive Not Recruiting2026-10-21
NCT04606446Study of PF-07248144 in Advanced or Metastatic Solid TumorspalbociclibPfizerRecruiting2026-10-21
NCT04661007To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants WlenalidomideIncyte Biosciences Japan GKActive Not Recruiting2026-10-21
NCT04671667Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chcarboplatin hexalNational Cancer Institute (NCI)Recruiting2026-10-21
NCT04671667Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of ChcisplatinNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07700758A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)belzutifanMerck Sharp & Dohme LLCRecruiting2026-10-21
NCT07679334Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast PhvenetoclaxRoswell Park Cancer InstituteNot Yet Recruiting2026-10-21
NCT03914612Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and CarboplcarboplatinNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment WifludarabineNational Cancer Institute (NCI)Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute LymphcytarabineNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute LymphdaunorubicinNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT04421560Pembrolizumab, Ibrutinib and Rituximab in PCNSLibrutinibDana-Farber Cancer InstituteRecruiting2026-10-21
NCT04421560Pembrolizumab, Ibrutinib and Rituximab in PCNSLpembrolizumabDana-Farber Cancer InstituteRecruiting2026-10-21
NCT04472949Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in ExtensivcarboplatinSwiss Cancer InstituteActive Not Recruiting2026-10-21
NCT04472949Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in ExtensivdurvalumabSwiss Cancer InstituteActive Not Recruiting2026-10-21
NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment WicytarabineNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05048797A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable,pembrolizumabAstraZenecaActive Not Recruiting2026-10-21
NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wicytarabine and daunorubicin liposomalNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment WidaunorubicinNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05061550Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancercarboplatinAstraZenecaRecruiting2026-10-21
NCT05061550Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancercisplatinAstraZenecaRecruiting2026-10-21
NCT05139017A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or RefractobendamustineMerck Sharp & Dohme LLCRecruiting2026-10-21
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabdacarbazineNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07887672A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed MultipledaratumumabKite, A Gilead CompanyNot Yet Recruiting2026-10-21
NCT07735637A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants WithlenalidomideAstraZenecaRecruiting2026-10-21
NCT07887672A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed MultipledexamethasoneKite, A Gilead CompanyNot Yet Recruiting2026-10-21
NCT07887672A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed MultiplefludarabineKite, A Gilead CompanyNot Yet Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiacyclophosphamideNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiapegaspargaseNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiamitoxantroneNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT06172296Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed thiotepaNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06279364A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic TriplecapecitabineSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Active Not Recruiting2026-10-21
NCT06203600Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialpaclitaxelNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06279364A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic TriplecarboplatinSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Active Not Recruiting2026-10-21
NCT05554406Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started TreatmenvenetoclaxNational Cancer Institute (NCI)Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemiathioguanine hydrateNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wigemtuzumab ozogamicinNational Cancer Institute (NCI)Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemiathioguanine hemihydrateNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiathioguanineNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT06317649Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH TreagilteritinibNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06317649Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH TreaazacitidineNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06317649Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH TreavenetoclaxNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06317662Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Ccalaspargase pegolNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory AggressprednisoneNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06834282CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)mesnaCERo Therapeutics Holdings, Inc.Recruiting2026-10-21
NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory AggresslenalidomideNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabbrentuximab vedotinNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressprednisone intensolNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06834282CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)cyclophosphamideCERo Therapeutics Holdings, Inc.Recruiting2026-10-21
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabetoposideNational Cancer Institute (NCI)Recruiting2026-10-21
NCT05675410A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabetoposide phosphateNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory AggressvenetoclaxNational Cancer Institute (NCI)Recruiting2026-10-21
NCT06654882Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisabataceptDuke UniversityRecruiting2026-10-21
NCT06654882Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritistofacitinibDuke UniversityRecruiting2026-10-21
NCT06679946A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyvutrisiranAlnylam PharmaceuticalsEnrolling By Invitation2026-10-21
NCT07884877PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancerdurvalumab plus tremelimumabSamsung Medical CenterRecruiting2026-10-21
NCT07885293A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPdasatinibJiangsu Hansoh Pharmaceutical Co., Ltd.Not Yet Recruiting2026-10-21
NCT07885293A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPimatinibJiangsu Hansoh Pharmaceutical Co., Ltd.Not Yet Recruiting2026-10-21
NCT07885293A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPnilotinibJiangsu Hansoh Pharmaceutical Co., Ltd.Not Yet Recruiting2026-10-21
NCT06995872Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refrairinotecan hydrochlorideNational Cancer Institute (NCI)Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemialeucovorinNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance CcarboplatinNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Ccarboplatin hexalNational Cancer Institute (NCI)Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute LymphthioguanineNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphcyclophosphamide monohydrateNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02112916Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphthioguanine hydrateNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT07885384Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy ifruquintinib combined with capecitabineWest China HospitalNot Yet Recruiting2026-10-21
NCT03122717Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancergefitinibDana-Farber Cancer InstituteActive Not Recruiting2026-10-21
NCT07735637A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants WithcyclophosphamideAstraZenecaRecruiting2026-10-21
NCT07730294Evaluating Intranasal Oxytocin (TNX-1900) for Pain Relief and Recovery After Pituitary SurgeryoxytocinYale UniversityNot Yet Recruiting2026-10-21
NCT07722611A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).ruxolitinibMerck Sharp & Dohme LLCRecruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiahydrocortisoneNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT07722611A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).ropeginterferon alfa-2bMerck Sharp & Dohme LLCRecruiting2026-10-21
NCT07549490Human Experimental Models of Pain (HEMP)naproxenNational Center for Complementary and Integrative Health (NCNot Yet Recruiting2026-10-21
NCT07549490Human Experimental Models of Pain (HEMP)pregabalinNational Center for Complementary and Integrative Health (NCNot Yet Recruiting2026-10-21
NCT07672483IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid TumorscetuximabNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07885397Sonrotoclax Plus Azacitidine in Patients With MDS-IB2azacitidineShanghai General Hospital, Shanghai Jiao Tong University SchRecruiting2026-10-21
NCT07885709MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCnivolumabPeking University People's HospitalNot Yet Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemiacyclophosphamide monohydrateNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT07672483IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid TumorscyclophosphamideNational Cancer Institute (NCI)Recruiting2026-10-21
NCT07659795A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancercetuximabVerastem, Inc.Recruiting2026-10-21
NCT07715903Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic ArtcarfilzomibNational Cancer Institute (NCI)Not Yet Recruiting2026-10-21
NCT07222761A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care CbortezomibRegeneron PharmaceuticalsRecruiting2026-10-21
NCT07672483IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid TumorsfludarabineNational Cancer Institute (NCI)Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiaetoposideNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiacytarabineNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiadexamethasoneNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT07879560Ramipril vs. Amlodipine in Pediatric Hemodialysis Patientsramipril tabletAin Shams UniversityNot Yet Recruiting2026-10-21
NCT07884734A Study to Evaluate the Effect of Carbamazepine or Itraconazole on Radiprodil in Healthy Adult ParticipantscarbamazepineGRIN Therapeutics, Inc.Active Not Recruiting2026-10-21
NCT07886905Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid CancerdabrafenibWashington University School of MedicineNot Yet Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiamercaptopurineNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT07885982Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBTanti-thymocyte globulinAnhui Provincial HospitalNot Yet Recruiting2026-10-21
NCT07885709MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCpemetrexedPeking University People's HospitalNot Yet Recruiting2026-10-21
NCT07886047Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancerpropranolol hydrochlorideSecond Xiangya Hospital of Central South UniversityRecruiting2026-10-21
NCT07351357Bisacodyl Oral for Lowering Dysfunction (of Tenckhoff Catheter)bisacodyl 5 mgChinese University of Hong KongRecruiting2026-10-21
NCT07880548Remimazolam vs Propofol for Long-Term Sedation in Mechanically Ventilated ICU Patientspropofol groupSun Yat-sen UniversityNot Yet Recruiting2026-10-21
NCT07882173Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton TyrosinepcoritamabNational Heart, Lung, and Blood Institute (NHLBI)Not Yet Recruiting2026-10-21
NCT07886801A Study of Ropeg-Interferon in People With Polycythemia VeraropeginterferonMemorial Sloan Kettering Cancer CenterNot Yet Recruiting2026-10-21
NCT02101853Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemiavincristine sulfateNational Cancer Institute (NCI)Active Not Recruiting2026-10-21
NCT07880548Remimazolam vs Propofol for Long-Term Sedation in Mechanically Ventilated ICU Patientspropofol medium/long-chain fat emulsion injectionSun Yat-sen UniversityNot Yet Recruiting2026-10-21
NCT05915104Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitisbudesonide mmx®University of CalgaryActive Not Recruiting2026-10-21

Request a quote

Nexara Health is a Health Canada–licensed pharmaceutical wholesaler (DEL #3-002896) based in Winnipeg, Manitoba, supplying hospitals, pharmacies, clinics, CROs, and trial sponsors across Canada. Send us the product, strength, presentation, and quantity for clinical trial comparator supply and we will come back with availability, source market, lead time, and landed cost — usually within 24 hours.

Request a sourcing quote or call +1 (431) 588-9055.

Related pages